Dominant negative mutants of IRS-1 and uses thereof

Details Dominant negative mutants of IRS-1 and uses thereof Dominant negative mutants of IRS-1 and uses thereof

1997-11-04

2003-03-04

Navarro, Mark (Department: 1645)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C514S003100, C530S350000

Reexamination Certificate

active

06528479

ABSTRACT:

FIELD OF THE INVENTION
This invention relates to signal transduction in mammalian cells.
BACKGROUND OF THE INVENTION
Human hepatocellular carcinoma (HCC) is one of the most common and least understood tumors. Although persistent hepatitis B and C virus infections are major risk factors for the development of this disease, little is known regarding cellular pathogenesis. Normal hepatocyte proliferation is regulated by several growth factors, of which insulin, epidermal growth factor (EGF), transforming growth factor &agr; (TGF&agr;) and hepatocyte growth factor (HGF) are believed to be the most important (Moradpour et al., IN:
Hepatology
, 3rd ed., W. B. Saunders, Philadelphia, Pa.). Such growth factors bind to hepatocyte cell surface receptors with intrinsic tyrosine kinase activity and initiate a series of protein phosphorylation events within the cells. Tyrosyl phosphorylation (TP) of downstream molecules transmits the mitogenic signals from the cell surface to the nucleus through several signal transduction pathways.
A cDNA encoding one of the key molecules involved in the insulin mediated signal transduction cascade, human insulin receptor substrate-1 (human IRS-1 or hIRS-1), has been found to be overexpressed at the protein and RNA levels in HCC cell lines and tumor tissues (Furusaka et al.,
Mol. Cell Biol
. 11:4405-4414, 1991; Nishiyama et al.,
Biochem. Biophys. Res. Commun
. 183:280-285, 1992). Tyrosine residues of IRS-1 are phosphorylated following cellular stimulation by ligands such as insulin; insulin-like-growth-factor 1 (IGF-1); interleukins 4, 9 and 13; interferons &agr; and &bgr;; growth hormone; leukemia inhibitory factor; and tumor necrosis factor (Artersinger et al.,
J. Biol. Chem
. 270:14685-14692, 1995; Guo et al.,
J. Biol. Chem
. 271:615-618, 1996; Myers et al.,
J. Biol. Chem
. 270:11715-11718, 1995; Platanias et al.,
J. Biol. Chem
. 271:278-282, 1996; Welham et al.,
J. Biol. Chem
. 270:12286-12296, 1995). Tyrosyl phosphorylated IRS-1 serves as a key “docking” protein. It transmits mitogenic or metabolic signals by interacting, through specific motifs, with downstream molecules containing the Src homology domain 2 (SH
2
) (Sun et al.,
Nature
377:173-177, 1995). For example, the
897
YVNI (SEQ ID NO:1) motif of hIRS-1 binds to the Grb2 adapter protein (Baltensperger et al.,
Science
260:1950-1952, 1993); the
1180
YIDL (SEQ ID NO:2) motif binds to Syp phosphatase (also known as PTP1D, PTP2C, and SH-PTP2) (Kuhne et al.,
J. Biol. Chem
. 268:11479-11481, 1993); and
613
YMPM (SEQ ID NO:3) and
942
YMKM (SEQ ID NO:4) motifs are the principal binding sites for the p85 subunit of phosphatidylinositol-3 kinase (PI3K) (Backer et al.,
EMBO J
. 11:3469-3479, 1992; Myers et al.,
Proc. Natl. Acad. Sci. USA
89:10350-10354, 1992). While TP sites are recognized throughout the entire IRS-1 protein, the SH
2
-binding domains are located only in the C-terminal region (Myers et al.,
Trends Biochem. Sci
. 19:289-293, 1994). The N-terminal sequences, however, contain three important functional domains identified as a pleckstrin homology (PH) region, located at amino acid residues 9-117 (Musacchio et al.,
Trends Biochem. Sci
. 18:343-348, 1993), and two regions homologous to a phosphotyrosine binding (PTB) domain, located at amino acid residues 161-317 (Sun et al.,
Nature
377:173-177, 1995) and at amino acid residues 314-463 (Gustafson et al.,
Mol. Cell. Biol
. 15:2500-2508, 1995).
Normal hepatic growth has been associated with TP of IRS-1 and its subsequent interaction with SH
2
-containing molecules such as Grb2 and PI3K during the G1 phase of the hepatocyte cell cycle following partial hepatectomy (Sasaki et al.,
J. Biol. Chem
. 268:3805-3808, 1993). There is now evidence to support the hypothesis that IRS-1 may have transforming properties as well (D'Ambrosio et al.,
Cell. Growth Differ
. 6:557-562, 1995; Ito et al.,
Mol. Cell. Biol
. 16:943-951, 1996). Stable transfection and overexpression of the hIRS-1 gene in NIH 3T3 cells leads to increased TP of the protein, enhanced binding of the protein to Grb2 and Syp but not PI3K, and persistent activation of the downstream MAPK (mitogen-activated protein kinase) cascade. Such transfected cells develop a phenotype characterized by increased transformed foci formation, induction of anchorage independent cell growth, increased cell proliferation and formation of large tumors in nude mice (Ito et al.,
Mol. Cell Biol
. 16:943-951, 1996). The functional domains of the hIRS-1 protein required for its transforming activity have been shown to reside in both the
897
YVNI (SEQ ID NO:2) and
1180
YIDL (SEQ ID NO:3) motifs (Tanaka et al.,
J. Biol. Chem
., 1996). Insulin and IGF-1 have been shown to act as dominant cellular mitogens for several different human tumors including HCC (Macaulay,
Br. J. Cancer
65:311-320, 1992).
SUMMARY OF THE INVENTION
The present invention is based on the discovery of the functional domains of mammalian IRS-1's that are essential for insulin- and IGF-1-induced TP and for subsequent activation of downstream signal transduction molecules associated with tumorigenicity. Applicants have also discovered that a dominant negative mutant protein derived from hIRS-1 blocks TP of endogenous hIRS-1 protein and other substrates of insulin- or IGF-1- induced TP (e.g., Shc). This mutant protein also reverses the malignant phenotype of HCC cells.
Accordingly, the invention features dominant negative mutants of mammalian (e.g., human) IRS-1 proteins. The mutants, when co-expressed with a wild type IRS-1 in a cell, block the function of the wild type IRS-1 in the cell. Dominant negative mutants substitute for wild-type proteins implicated in pathogenicity and can counteract their pathogenic effects.
The mutants of the invention can contain the pleckstrin homology domain and the two phosphotyrosine binding domains of their corresponding wild type IRS-1's. For instance, a dominant negative mutant of human IRS-1 can contain 460 amino acid residues from the amino-terminal half (i.e., amino acid residues 1-621) of native IRS-1. The pleckstrin homology (PH) domain corresponds approximately to amino acid residues 9-117 of hIRS-1, and is believed to bring IRS-1 to close proximity to cell membranes on which insulin receptor resides. The two phosphotyrosine domains (PTB) correspond approximately to amino acid residues 161-314 and 315-463 of hIRS-1, respectively. The PTB domains, when bound to insulin receptor, become phosphorylated at their tyrosine residues. IRS-1 thus phosphorylated can transmit the signal from the insulin receptor via the IRS-1′ SH
2
-binding region to proteins residing downstream in the insulin/IGF-1 signal transduction pathway.
The mutant protein may also lack at least one or even all of the functional SH
2
-binding motifs at its SH
2
-binding region, so that the protein can no longer bind to the SH
2
domain of one or all of its adaptor proteins (e.g., Syp, Grb2, PI3K, or NCK). For instance, a dominant negative mutant of human IRS-1 may lack at least 300 amino acid residues from its carboxy-terminal half (i.e., amino acid residues 622-1243). It may even lack the last 727 amino acid residues of human IRS-1.
The mutant can additionally contain a heterologous sequence, i.e., a sequence not related to IRS-1, to facilitate its identification or purification. The heterologous sequence may contain an epitope to which an antibody can bind, or a ligand (e.g., a maltose-binding protein domain or a His tag) of any other receptor molecule (e.g., maltose or nickel). This sequence can range from, e.g., 4-25 amino acid residues in length, and replace 0-25 amino acid residues of the IRS-1 sequence in the mutant protein. It will typically be at one end of the mutant protein, but can be in the middle. Exemplary epitopes include FLAG, E-tag, c-myc tag, VSV-GP, T7 tag, HSV tag, and HA tag, all of which are well known in the art. The identity of the tag sequence is not critical.
Due to polymorphism that may exist at the IRS-1 genetic locus, minor variations in the amino acid sequence of t

Affiliated with

Also associated with

Rating

Dominant negative mutants of IRS-1 and uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Dominant negative mutants of IRS-1 and uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Dominant negative mutants of IRS-1 and uses thereof will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3086268